Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|Dossier withdrawn by the notifier
|Non-replicating recombinant vector derived from adeno-associated virus AAV6 serotype, containing a codon-optimised version of the human Factor VIII gene
|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
|Non-replicating recombinant vector derived from adeno-associated virus AAV9, lacking all AAV viral genes and containing a miniaturized version of the human dystrophin gene
|Only notified under the "contained use" procedure. Dossier submitted on 14/10/2015.
|A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
|Novartis Pharma Services AG
|Chimeric antigen receptor against CD19
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2015.
|A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
|Catapult Cell Therapy
|Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)